Akyüz Canan, Varan Ali, Küpeli Serhan, Akalan Nejat, Söylemezoglu Figen, Zorlu Faruk, Kutluk Tezer, Büyükpamukçu Münevver
Department of Pediatric Oncology, Hacettepe University, Institute of Oncology, 06100 Ankara, Turkey.
J Neurooncol. 2008 Oct;90(1):99-103. doi: 10.1007/s11060-008-9638-x. Epub 2008 Jun 20.
We retrospectively evaluated 203 patients newly diagnosed with medulloblastoma between 1975 and 2006. All patients underwent surgical resection and after surgery were treated with a combination of radiotherapy and chemotherapy. CCNU-based protocols were used in the early years, with CDDP+VP16 being used more recently. Radiotherapy was used in patients older than three years of age according to the protocols. One hundred fifteen patients had total surgical resection, 78 had subtotal resection, and 4 patients had only a biopsy. Every patient received chemotherapy: 124 with the CCNU-based protocol, 75 with CDDP+VP16, and 4 with other protocols. Overall (OS) and event free-survival (EFS) rates were 43.1 and 41.9% in the whole group, with a median follow-up time of 8 years. OS rates for patients with and without spinal seeding were 30 and 63.1% (P = 0.0002). OS rates for males and females were 36.2 and 54.7% (P = 0.03). OS rates for patients receiving the CCNU and CDDP+VP16 protocols were 41.1 and 45%.
我们回顾性评估了1975年至2006年间新诊断为髓母细胞瘤的203例患者。所有患者均接受了手术切除，术后接受放疗和化疗联合治疗。早期采用基于洛莫司汀的方案，最近则使用顺铂+依托泊苷。根据方案，对3岁以上患者使用放疗。115例患者接受了全切除，78例接受了次全切除，4例仅进行了活检。每位患者均接受化疗：124例采用基于洛莫司汀的方案，75例采用顺铂+依托泊苷，4例采用其他方案。全组的总生存率（OS）和无事件生存率（EFS）分别为43.1%和41.9%，中位随访时间为8年。有和无脊髓播散患者的OS率分别为30%和63.1%（P = 0.0002）。男性和女性的OS率分别为36.2%和54.7%（P = 0.03）。接受洛莫司汀和顺铂+依托泊苷方案患者的OS率分别为41.1%和45%。
